Pluri
Andy Lewin has a diverse work experience spanning over several companies and roles. Andy is currently serving as the Chief Commercial Officer at Pluri since October 2023. Prior to that, they held the role of Chief Business Officer at Gene and Ascend GCTX in Ascend from July 2022 to June 2023. Andy also worked as a Board Member at SSNAP, a charity supporting the Newborn Intensive Care Unit at the John Radcliffe Hospital in Oxford, UK, from April 2012 to November 2022. Additionally, they held various positions such as VP Business Development, Manufacturing at Oxford Biomedica from August 2018 to June 2022, Vice President Business Development at AGC Biologics from July 2012 to August 2018, Vice President Business Development PDS at NextPharma from September 2011 to July 2012, Senior Business Development Manager at OctoPlus from January 2010 to September 2011, Head of Sales and Marketing at BioOutsource from January 2008 to September 2009, Business Development and Project Management Director at SynCo Bio Partners from June 2004 to November 2007, and Director of Business Development at Cobra Biomanufacturing from an unknown start date to 2004.
Andy Lewin obtained a Bachelor of Arts degree in Biochemistry from the University of Oxford, where they studied from 1983 to 1987.
This person is not in any offices
Pluri
3 followers
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.